Michael S Perry
CIK 1250379 · Chief Executive Officer · last filed 2026-08-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARWR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
196 BOSTON AVE SUITE 2800
MEDFORD, MA 02155
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARWR | Director | 111,459 | $58.16 | $6.48M | -$9.33M | 25 | 2026-08-20 |
| RCEL | Chief Executive Officer | 406,525 | $16.59 | $6.74M | -$3.81M | 9 | 2022-11-22 |
| ARMP | Director | — | $3.51 | — | $0 | 1 | 2019-05-24 |
| Armata Pharmaceuticals, Inc. (APHB) Delisted | Director | 29,381 | — | — | $200.0K | 3 | 2018-03-26 |
| PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | President & CMO | 81,860 | — | — | -$16.9K | 7 | 2011-04-14 |
| TGEN | Director | 20,000 | $1.72 | $34.4K | $0 | 3 | 2009-06-02 |
Recent Filings · Page 5 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-03-27 | — | Exer (M) | +2,800 | $0 | |
| 2012-02-21 | ARWR | Grant (A) | — | $0 | EDGAR |
| 2012-02-17 | — | Sell (S) | −6,346 | -$5.5K | |
| 2012-02-17 | — | Exer (M) | +12,019 | $0 | |
| 2011-04-14 | PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Sell (S) | −45,140 | -$16.9K | EDGAR |
| 2011-04-12 | PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Exer (M) | +112,000 | $0 | EDGAR |
| 2011-03-15 | PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-02-16 | PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-08-03 | PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2010-06-02 | — | Grant (A) | +50,000 | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.